STML - Stemline Therapeutics, Inc.

NasdaqCM - NasdaqCM Delayed price. Currency in USD
14.15
-0.10 (-0.70%)
At close: 4:00PM EST

13.95 -0.20 (-1.41%)
After hours: 6:21PM EST

Stock chart is not supported by your current browser
Previous close14.25
Open13.65
Bid13.70 x 500
Ask14.00 x 100
Day's range13.40 - 14.65
52-week range5.50 - 16.20
Volume612,560
Avg. volume279,077
Market cap357.81M
Beta1.22
PE ratio (TTM)N/A
EPS (TTM)-2.59
Earnings date14 Mar 2018 - 19 Mar 2018
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est33.67
Trade prices are not sourced from all markets
  • Globe Newswireyesterday

    Stemline Therapeutics Announces Proposed Public Offering of Common Stock

    Stemline Therapeutics, Inc. (Nasdaq:STML), a clinical-stage biopharmaceutical company developing novel oncology therapeutics, today announced that it intends to offer and sell, subject to market conditions, 3,700,000 shares of its common stock in an underwritten public offering. In addition, Stemline intends to grant the underwriters a 30-day option to purchase up to an additional 555,000 shares of its common stock offered in the public offering. J.P. Morgan Securities LLC and Cowen and Company, LLC are acting as joint book-running managers for the offering.

  • Globe Newswire15 days ago

    Detailed Research: Economic Perspectives on Fluidigm, Stemline Therapeutics, NeoGenomics, CVR Energy, W.R. Berkley, and Mack-Cali Realty — What Drives Growth in Today's Competitive Landscape

    NEW YORK, Jan. 09, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Fluidigm Corporation (NASDAQ:FLDM), Stemline Therapeutics, Inc. (NASDAQ:STML), NeoGenomics, Inc. (NASDAQ:NEO), CVR Energy Inc. (NYSE:CVI), W.R. Berkley Corporation (NYSE:WRB), and Mack-Cali Realty Corporation (NYSE:CLI), including updated fundamental summaries, consolidated fiscal reporting, and fully-qualified certified analyst research.

  • Business Wire15 days ago

    Newman Ferrara LLP Announces Corporate Governance Investigation of Stemline Therapeutics Inc. - STML

    Newman Ferrara LLP announced today that the firm is conducting an investigation on behalf of shareholders of Stemline Therapeutics Inc. into potential breaches of fiduciary duty by the Company’s Board of Directors .

  • Globe Newswire19 days ago

    Stemline Therapeutics to Present at the 36th Annual J.P. Morgan Healthcare Conference

    NEW YORK, Jan. 04, 2018 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML), a clinical-stage biopharmaceutical company developing novel therapeutics for difficult to treat cancers announced today that Ivan Bergstein, M.D., Stemline’s CEO, will present at the 36th Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2018 at 9:30 AM PT (12:30 PM ET) at the Westin St. Francis Hotel in San Francisco, CA. A live webcast of the presentation can be viewed on the company's website at www.stemline.com.

  • MarketWatchlast month

    Stemline Therapeutics shares jump 4% premarket after positive trial of leukemia treatment

    Shares of biotech Stemline Therapeutics Inc. jumped 4% premarket Wednesday, after the company said a trial of a treatment for acute myeloid leukemia met its main goal. Stemline said data from the trial ...

  • Associated Press2 months ago

    Stemline Therapeutics reports 3Q loss

    The New York-based company said it had a loss of 68 cents per share. The results missed Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was for a ...

By using Yahoo you agree that Yahoo and partners may use Cookies for personalisation and other purposes